CCL5 and neoplasm: Treatment with this monoclonal antibody decreased levels of GZMB/CCL5 expressed per CD4+ T cell harvested from T3 (Fig. 4c,d) or F244 tumour-bearing mice (Extended Data Fig. 6e).